2650 participants
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2016-04-11
- Start Date:
- 2015-12-31
- Completion:
- 2015-12-31
Conditions
- Chronic Myeloid Leukemia (CML)
Interventions
- DRUG
No Results Yet